Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis

Vanessa Deveaux(Université Paris-Est Créteil), Sophie Lotersztajn(Inserm), Philippe Gual(Inserm), Patrick C. Even(Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement), Rémy Burcelin(Inserm), Jeanne Tran-Van Nhieu(Université Paris-Est Créteil), Marie‐Pierre Belot(Université Paris-Est Créteil), Y. Le Marchand‐Brustel(Inserm), Andreas Zimmer(University of Bonn), Patrice D. Cani(Walloon Excellence in Lifesciences and Biotechnology), Yasukatsu Ichigotani(Université Paris-Est Créteil), Thomas Cadoudal(Université Toulouse III - Paul Sabatier), Fatima Teixeira-Clerc(Inserm), Sylvie Manin(Inserm), Adeline Bertola(Université Côte d'Azur), Ariane Mallat(Centre Hospitalier Universitaire d'Angers), Claude Knauf(Université Toulouse III - Paul Sabatier), Alexandre Louvet(Inserm)
PLoS ONE
June 8, 2009
10.1371/journal.pone.0005844
Cited by 218

Related Papers

Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability
|Gut|2009|2.5k
IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice
|Nature|2002|2.1k
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug
|Nature Medicine|2017|1.6k
Human gut microbiome: hopes, threats and promises
|Gut|2018|1.4k
The stomach is a source of leptin
|Nature|1998|1.2k